Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UMC 119 06

Next Previous
Drug Profile

UMC 119 06

Alternative Names: Human umbilical cord derived-mesenchymal stem cell therapy; UMC 119-06; UMC119-06-05

Latest Information Update: 18 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meridigen Biotech
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Phase I/II Unspecified
  • Phase I Osteoarthritis
  • No development reported Acute kidney injury; Ischaemic stroke; Renal failure; Respiratory distress syndrome

Most Recent Events

  • 11 Jun 2024 Phase-II clinical trials in Chronic obstructive pulmonary disease in Taiwan (IV) (NCT04206007)
  • 03 Jun 2024 Phase-I/II clinical trials in Unspecified (Second-line therapy or greater, In the elderly) in Taiwan (IV) (NCT06501066)
  • 09 Sep 2023 Interim efficacy and adverse events data from a phase I trial in Chronic obstructive pulmonary disease presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top